Novo Nordisk Sues Hims & Hers Over Patent Infringement for Wegovy Pill

Novo Nordisk (NVO) filed a lawsuit against Hims & Hers (HIMS) on February 9, 2026, alleging patent infringement regarding compounded versions of Wegovy. The legal action forced the telehealth provider to abandon plans for a $49 monthly compounded pill after the FDA threatened enforcement actions against mass compounding. Novo holds exclusive FDA approval for the oral GLP-1 weight-loss drug, currently priced at $149 per month. The company cited safety concerns, reporting tests found up to 86% impurities in compounded ingredients. On February 6, 2026, HHS referred Hims & Hers to the Justice Department for investigation. The dispute precedes potential market entry by Eli Lilly’s competing oral weight-loss drug, orforglipron, expected to face FDA review in April 2026.